Vilket är priset för Poseida Therapeutics, Inc. (PSTX)

Priset för Poseida Therapeutics, Inc. (PSTX) är $9.50

Vilket är marknadsvärdet för Poseida Therapeutics, Inc. (PSTX)

Marknadsvärdet för Poseida Therapeutics, Inc. (PSTX) är $819.52M

Poseida Therapeutics, Inc. (PSTX) Vinst

Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.

År	Vinst	Ändra
2026 (TTM)	$-60.72M	-50.77%
2023	$-123.32M	94.34%
2022	$-63.46M	50,676.96%
2021	$-124.97K	-3.70%
2020	$-129.78K	-99.85%
2019	$-86.53M	93.98%
2018	$-44.61M	120.94%
2017	$-20.19M	278.07%
2016	$-5.34M	0.00%

År

Vinst

Ändra

2026 (TTM)

$-60.72M

-50.77%

2023

$-123.32M

94.34%

2022

$-63.46M

50,676.96%

2021

$-124.97K

-3.70%

2020

$-129.78K

-99.85%

2019

$-86.53M

93.98%

2018

$-44.61M

120.94%

2017

$-20.19M

278.07%

2016

$-5.34M

0.00%

Företag	Vinst	Skillnad i vinst	Land
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-8,787.83%	US
Argenx SE ARGX.US	$1.95B	-3,312.74%	NL
CSL Limited CSL.AX	$-4.02B	6,514.73%	AU
Moderna, Inc. MRNA.US	$-3.09B	4,984.33%	US
Lonza Group AG LONN.SW	-	-	CH

Företag

Vinst

Skillnad i vinst

Land